Overcoming the blood-brain barrier to treat Parkinson’s disease

Written by Lauren Pulling

A novel drug delivery system that bypasses the blood-brain barrier (BBB) will be used in combination with Herantis Pharma Plc’s (Helsinki, Finland) drug candidate CDNF for the treatment of Parkinson’s disease (PD) in upcoming Phase I-II clinical trials. The study will be supported by a €6 million Horizon 2020 grant, an innovation from the European Union. The drug delivery system, designed by Renishaw (Gloucestershire, UK) in partnership with leading neurosurgeons, bypasses the BBB by delivering drugs directly into brain tissue. Eighteen patients will take part in the study and receive the drug via a small port implanted into the skull...

To view the full article, please register now for access

It's completely free